Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for UCART20x22 in Cancer, Non-Hodgkin lymphoma. The expected timing is based on the latest available company guidance and may change.
NatHaLi-01 trial. Currently enrolling patients. Presented poster at ASH'23. 11/06/23- Trial ongoing. 8/4/25- Present data in late 2025. Poster presentation at ASH'25 on Dec 7, 2025. 11/07/25:- R&D Day data show 86% ORR, 57% CR; full Ph1 NatHaLi-01 dataset planned in 2026. 12/08/25:- ASH 2025 Ph1 NATHALI-01 data: ORR 88%, CR 63%; IL-2 cohort starts Q1 2026; full dataset 2026. 05/12/26:- NATHALI-01 EHA poster Jun 13, 2026. Ph1 clinical data disclosure planned Q4 2026. 05/11/26:- NATHALI-01: 88% ORR, 63% CR; 93% had prior CD19 CAR-T; EHA 2026 poster Jun 13; full Ph1 dataset Q4 2026. 06/11/26:- Feb 2026 cutoff shows 88% ORR, 63% CR; EHA poster Jun 13, 2026; full Ph1 data Q4 2026. 08/06/26:- NATHALI-01 translational data presented; full Ph1 dataset expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.